Michael Sokol, MD
Endocrinology, Diabetes & Metabolism · Overland Park, KSNPI 1235163676
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $175,798 of the $227,388 with a category attached, or 77.3%. 60 manufacturers reported payments, led by Lilly USA, LLC at 37.7% of the total. Reporting peaked in 2022 at $69,979 and has fallen 81.2% since, to $13,170 in 2025. Among endocrinology, diabetes & metabolism clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,460 payments — averaging $155.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$86K
- Novo Nordisk$42K
- Johnson & Johnson$21K
- Abbott$18K
- AstraZeneca$14K
- Mannkind Corporation$11K
- plus $36K from 54 others
What the payments were for
- Consulting fees$10,4285%
- Speaking & faculty fees$175,79877%
- Travel & lodging$15,6417%
- Food & beverage$25,32911%
- Education$1920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$227,388 in reported general payments places this provider in the 95th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 574 | $926,157 |
| MounjaroTirzepatide | 258 | $443,974 |
| TrulicityDulaglutide | 174 | $338,761 |
| Metyrosine | 12 | $335,835 |
| JardianceEmpagliflozin | 134 | $190,763 |
| FarxigaDapagliflozin Propanediol | 143 | $190,288 |
| Gvoke Hypopen 2-PackGlucagon | 12 | $171,728 |
| Tresiba Flextouch U-100Insulin Degludec | 229 | $165,456 |
| RybelsusSemaglutide | 62 | $97,533 |
| SynjardyEmpagliflozin/Metformin Hcl | 67 | $86,765 |
| Bydureon BciseExenatide Microspheres | 46 | $68,222 |
| JanuviaSitagliptin Phosphate | 44 | $64,178 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 34 | $47,324 |
| InvokanaCanagliflozin | 32 | $43,450 |
| Xigduo XrDapaglifloz Propaned/Metformin | 34 | $41,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $41,533 | $1,035,993673 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $85,783 | $791,083467 claims |
| Boehringer IngelheimJardiance, Synjardy, Tradjenta, Glyxambi | $410 | $312,270235 claims |
| AstraZenecaFarxiga | $13,526 | $190,288143 claims |
| MerckJanuvia, Janumet | $238 | $79,09255 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,018 | $47,32434 claims |
| Johnson & JohnsonInvokana | $20,727 | $43,45032 claims |
| PfizerGenotropin | $782 | $21,58929 claims |
| Mannkind CorporationAfrezza | $11,390 | $21,25813 claims |
| BayerKerendia | $5,716 | $19,99618 claims |
| Antares Pharma, Inc.Tlando | $260 | $19,38824 claims |
| AbbVieSynthroid | $1,575 | $18,345214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Overland Park
- Sajeev MenonOverland Park$25K
- M Yaser MounlaOverland Park$9K
- Mini AbrahamOverland Park$550
- Marie GriffinOverland Park$303
- Jeffrey KallsenOverland Park$80
- Dany ZayourWichita$744K
- Andrew GreenShawnee Mission$322K
- Rami MortadaWichita$105K
- Georges ElhomsyWichita$14K
- Richard GomendozaSalina$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.